Last reviewed · How we verify
NCT05408780
A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects
Phase 1 trial testing AC-OLE-01-VA in Alzheimer Disease in 45 participants. Completed in 24 October 2022.
13 August 2022
Quick facts
| Lead sponsor | Cerecin |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 45 |
| Start date | 14 July 2022 |
| Primary completion | 13 August 2022 |
| Estimated completion | 24 October 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- AC-OLE-01-VA — full drug profile →
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
Cerecin — full company profile →
Who can join
Adults 18 to 55, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the PK, safety, and tolerability of a new liquid formulation of tricaprilin.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Alzheimer's disease drug development pipeline: 2023.
Cummings J, Zhou Y, Lee G, Zhong K, et al · · 2023 · cited 326× · PMID 37251912 · DOI 10.1002/trc2.12385
Verify or expand the search:
- PubMed search for NCT05408780
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AC-OLE-01-VA
Trials testing the same drug.
- NCT05628636 — AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions · Phase 1 · completed
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Cerecin trials
Trials by the same sponsor.
- NCT05628636 — AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions · Phase 1 · completed
- NCT04187547 — A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Diseas · Phase 3 · withdrawn
- NCT04727970 — Tricaprilin Infantile Spasms Pilot Study · Phase 1 · completed
- NCT05028114 — Tricaprilin Liquid Formulation PK Study · Phase 1 · terminated
- NCT04437199 — Tricaprilin Phase 2 Pilot Study in Migraine · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05408780 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cerecin
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05408780.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing